Compounded bioidentical hormone therapy: Identifying use trends and knowledge gaps among US women

Menopause

Volumn 22, Issue 9, 2015, Pages 926-936

  Pinkerton, Jo Ann V ^a   Santoro, Nanette ^b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Bioidentical; Compounded hormone therapy; Hot flashes; Menopause; Vasomotor symptoms

Indexed keywords

HORMONE;

ADULT; ARTICLE; FEMALE; FOOD AND DRUG ADMINISTRATION; HEALTH SURVEY; HORMONAL THERAPY; HUMAN; KNOWLEDGE; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MENOPAUSAL SYNDROME; PHYSICIAN; POSTMENOPAUSE; PRESCRIPTION; UNITED STATES; AGED; ATTITUDE TO HEALTH; DRUG APPROVAL; DRUG FORMULATION; ESTROGEN THERAPY; MENOPAUSE; MIDDLE AGED; QUESTIONNAIRE; VERY ELDERLY; WOMEN'S HEALTH;

ADULT; AGED; AGED, 80 AND OVER; DRUG APPROVAL; DRUG COMPOUNDING; ESTROGEN REPLACEMENT THERAPY; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; MENOPAUSE; MIDDLE AGED; SURVEYS AND QUESTIONNAIRES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; WOMEN'S HEALTH;

EID: 84946570882     PISSN: 10723714     EISSN: 15300374     Source Type: Journal    
DOI: 10.1097/GME.0000000000000420     Document Type: Article

References (51)

1. The North American Menopause Society. The 2012 hormone therapy position statement of The North American Menopause Society. Menopause 2012; 19: 257-271
2. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333
3. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA 2013; 310: 1353-1368
4. Sprague BL, Trentham-Dietz A, Cronin KA. A sustained decline in postmenopausal hormone use: results from the National Health and Nutrition Examination Survey, 1999-2010. Obstet Gynecol 2012; 120: 595-603
5. Steinkellner AR, Denison SE, Eldridge SL, et al. A decade of postmenopausal hormone therapy prescribing in the United States: longterm effects of the Women's Health Initiative. Menopause 2012; 19: 616-621
6. Stagnitti M, Lefkowitz D. Trends in Hormone Replacement Therapy Drug Utilization and Expenditures for Adult Women in the US Civilian Noninstitutionalized Population, 2001-2008. Rockville, MD Agency for Healthcare Research and Quality; 2011; 1-9
7. Jungheim ES, Colditz GA. Short-Term use of unopposed estrogen: a balance of inferred risks and benefits. JAMA 2011; 305: 1354-1355
8. Jewett PI, Gangnon RE, Trentham-Dietz A, et al. Trends of postmenopausal estrogen plus progestin prevalence in the United States between 1970 and 2010. Obstet Gynecol 2014; 124: 727-733
9. Committee on Gynecologic Practice and the American Society for Reproductive Medicine Practice Committee. Committee opinion no. 532: compounded bioidentical menopausal hormone therapy. Obstet Gynecol 2012; 120: 411-415
10. MacLennan AH, Gill TK, Broadbent JL, et al. Continuing decline in hormone therapy use: population trends over 17 years. Climacteric 2009; 12: 122-130
11. Pinkerton JV. Bioidentical'' hormones. What you (and your patient) need to know. OBG Manag 2009; 21: 42-52
12. Boothby LA, Doering PL, Kipersztok S. Bioidentical hormone therapy: a review. Menopause 2004; 11: 356-367
13. Complaint by the State of Tennessee vs HRC Medical Centers, Case No. 12C4047. Available at: http://www.tn.gov/attorneygeneral/cases/hrc/hrcamendedcomplaint.pdf. April 15, 2013. Accessed June 30, 2014
14. To: Oprah Winfrey; subject: hormones. What I know for sure. Available at: http://www.oprah.com/spirit/What-Oprah-Knows-for-Sure-About-Menopause-And-Hormones. Accessed June 30, 2014
15. Somers S. Bioidentical hormones and wellness. Available at: http://www.suzannesomers.com/pages/forever-health. Accessed June 30, 2014
16. Musgrave J. Not guilty: steroid doctor, pharmacist cleared on all counts. Palm Beach Post 2014. Available at: http://www.mypalmbeachpost.com/news/news/crime-law/doctor-And-pharmacist-Acquitted-of-All-chargesin-/ndF4B. Accessed June 30, 2014
17. Roser MA. Ethical questions raised as doctors partner with pharmacies. Austin American-Statesman 2013. Available at: http://www.mystatesman. com/news/news/local/ethical-questions-raised-As-doctors-partnerwith-p/nbndb. Accessed June 14, 2014
18. Bioidentical hormones: sound science of bad medicine? Senate hearing before the Special Committee onAging, 110th Congress, First Session, 2007
19. Iftikhar S, Shuster LT, Johnson RE, et al. Use of bioidentical compounded hormones for menopausal concerns: cross-sectional survey in an academic menopause center. J Womens Health (Larchmt) 2011; 20: 559-565
20. Baker R, Blumberg S, Coupler MP for the AAPOR Standards Committee Task Force. AAPOR report on online panels. Available at http://www. aapor.org/AAPORKentico/AAPOR-Main/media/MainSiteFiles/AAPOROnlinePanelsTFReportFinalRevised1.pdf. Accessed September 15, 2014
21. US Census Bureau. Annual estimates if the resident population by single year of age and sex for the United States: April 1, 2010 to July 1, 2012. Available at: http://factfinder2.census.gov/faces/tableservices/jsf/pages/productview.xhtml?pid=PEP-2012-PEPSYASEXN& prodType=table. Accessed June 15, 2014
22. Barenberg BJ, Smith T, Nihira MA. Compounded estradiol cream: a cost conscious alternative. J Okla State Med Assoc 2014; 107: 155-156
23. BodyLogicMD. If I decide to start on a bioidentical hormone therapy program, how much will it cost? Available at: http://www.bodylogicmd. com/faq/if-i-decide-To-start-on-A-bioidentical-hormone-Therapy-programhow-much-will-it-cost. 2014. Accessed August 5, 2014
24. Gold EB, Colvin A, Avis N, et al. Longitudinal analysis of the association between vasomotor symptoms and race/ethnicity across the menopausal transition: Study of Women's Health Across the Nation. Am J Public Health 2006; 96: 1226-1235
25. Guthrie JR, Dennerstein L, Taffe JR, et al. Hot flushes during the menopause transition: a longitudinal study in Australian-born women. Menopause 2005; 12: 460-467
26. Freeman EW, Sammel MD, Sanders RJ. Risk of long-Term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause 2014; 21: 924-932
27. The North American Menopause Society. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013; 20: 888-902
28. The Endocrine Society. The Endocrine Society position statement on bioidentical hormones. Available at: https://www.endocrine.org/-/media/endosociety/Files/Advocacy%20and%20Outreach/Position%20-Statements/All/BH-Position-Statement-final-10-25-06-w-Header.pdf. October 2006. Accessed April 11, 2014
29. US Food and Drug Administration. Bio-identicals: sorting myths from facts. Available at: http://www.fda.gov/ForConsumers/ConsumerUpdates/ucm049311.htm. December 7, 2013. Accessed April 14, 2014
30. Cirigliano M. Bioidentical hormone therapy: a review of the evidence. J Womens Health 2007; 16: 600-631
31. Buist DS, Newton KM, Miglioretti DL, et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 2004; 104: 1042-1050
32. Boothby LA, Doering PL. Bioidentical hormone therapy: a panacea that lacks supportive evidence. Curr Opin Obstet Gynecol 2008; 20: 400-407
33. Adams C, Cannell S. Women's beliefs about ''natural'' hormones and natural hormone replacement therapy. Menopause 2001; 8: 433-440
34. Spark MJ, Willis J, Byrne G. Compounded progesterone: why is it acceptable to Australian women? Maturitas 2012; 73: 318-324
35. Siyam T, Yuksel N. Beliefs about bioidentical hormone therapy: a crosssectional survey of pharmacists. Maturitas 2013; 74: 196-202
36. Sayakhot P, Vincent A, Teede H. Breast cancer and menopause: perceptions of diagnosis, menopausal therapies and health behaviors. Climacteric 2012; 15: 59-67
37. Gibson-Helm M, Teede H, Vincent A. Symptoms, health behavior and understanding menopause therapy in women with premature menopause. Climacteric 2014; 17: 1-8
38. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance: pharmacy compounding of human drug products under Section 503A of the Federal Food, Drug, and Cosmetic Act. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM377052.pdf. July 2014. Accessed April 5, 2013
39. Moyer VA, USPreventive Services Task Force. Menopausal hormone therapy for the primary prevention of chronic conditions: US Preventive Services Task Force recommendation statement. Ann Intern Med 2013; 158: 47-54
40. Cobin RH, Petak SM, Bledsoe MB. American Association of Clinical Endocrinologists (AACE) ReproductiveMedicine Committee position statement on bioidentical hormones.Available at: https://www.aace.com/files/position-statements/aacebhstatement071507.pdf. Accessed September 26, 2014
41. McBane SE, Borgelt LM, Barnes KN, et al. Use of compounded bioidentical hormone therapy in menopausal women: an opinion statement of the Women's Health Practice and Research Network of the American College of Clinical Pharmacy. Pharmacotherapy 2014; 34: 410-423
42. De Villiers TJ, Pines A, Panay N, et al. Updated 2013 International Menopause Society recommendations on menopausal hormone therapy and preventive strategies for midlife health. Climacteric 2013; 16: 316-337
43. Australian Menopause Society. Bioidentical hormones for menopausal symptoms information sheet. Available at: http://www.menopause. org.au/images/stories/infosheets/docs/AMS-Bioidentical-Hormones-for-Menopausal-Symptoms.pdf. Accessed September 26, 2014
44. Panay N, Hamoda H, Arya R, et al. The 2013 British Menopause Society& Women's Health Concern recommendations on hormone replacement therapy. Menopause Int 2013; 19: 59-68
45. Sellers S, Utian WH. Pharmacy compounding primer for physicians: prescriber beware. Drugs 2012; 72: 2043-2050
46. McKenna KJ. Compounded sclerosing agents: risks and consequences. Vein 2008; 1: 1. Available at: http://www.veindirectory.org/magazine/article/compounded-sclerosing-Agents-risks-And-consequences. Accessed August 11, 2014
47. The Pew Research Center. Assessing the representativeness of public opinion surveys. Available at: http://www.people-press.org/files/legacypdf/Assessing%20the%20Representativeness%20of%20Public%20Opinion%20Surveys.pdf. Accessed November 4, 2014
48. Yeager DS, Krosnick JA, Chang L. Comparing the accuracy of RDD telephone surveys and Internet surveys conducted with probability and nonprobability samples. Public Opin Q 2011; 75: 709-747
49. Sandini L, Pentti K, Tuppurainen M, et al. Agreement of self-reported estrogen use with prescription data: an analysis of women from the Kuopio Osteoporosis Risk Factor and Prevention Study. Menopause 2008; 15: 282-289
50. Banks E, Beral V, Cameron R, et al. Agreement between general practice prescription data and self-reported use of hormone replacement therapy and treatment for various illnesses. J Epidemiol Biostat 2001; 6: 357-363
51. Lokkegaard E, Johnsen SP, Heitmann BL, et al. The validity of selfreported use of hormone replacement therapy among Danish nurses. Acta Obstet Gynecol Scand 2004; 83: 476-481